Trial Profile
A Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in Japan
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 May 2022
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Pyoderma gangrenosum
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 01 May 2022 Results of a final analysis, 52-week, published in the Journal of Dermatology
- 27 Nov 2020 Results published in the AbbVie, Eisai Co Ltd Media Release.
- 27 Nov 2020 According to an AbbVie, Eisai Co Ltd media release, the companies announced approval of additional indication of HUMIRA(generic name: adalimumab [recombinant]) for the treatment of pyoderma gangrenosum. This approval of the additional indication is based on the data from this Japanese phase III clinical trial conducted in Japanese patients.